Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 21 Jan 2020 9:22 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act providing funding to the Department of Defense ALSRP to support innovative and impactful research to develop new treatments for ALS.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

     

    FY20 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.    

    https://cdmrp.army.mil/funding/alsrp

     

    Therapeutic Development Award - Pre-Application March 27, 2020

    Independent investigators at all academic levels (or equivalent)

    ·      Pre-application is required; full application submission is by invitation only.

    ·      Supports preclinical secondary validation and IND-enabling studies of therapeutics for ALS.

    ·      Preliminary data is required, including efficacy in at least one ALS-relevant model system with a lead molecule/class of compounds.

    ·      Biomarker development and/or characterization (if not already validated), in parallel to the main therapeutic effort, is a critical component of the TDA proposal.

    ·      Maximum funding of $1,000,000 for direct costs plus indirect costs

    ·      Maximum period of performance is years

     

    Therapeutic Idea Award - Pre-Application March 27, 2020

    Independent investigators at all academic levels (or equivalent)

    ·      Pre-application is required; full application submission is by invitation only.

    ·      Supports hypothesis-driven preclinical therapeutic development.

    ·      Preliminary data are not required.

    ·      Projects focusing primarily on investigating ALS pathophysiology are outside the scope of this award mechanism.

    ·      Early Career Investigators are encouraged to apply.

    ·      Therapeutic Relevant Biomarker Option: Applications which include the development of biomarkers in parallel with the main therapeutic advancement effort, and that meet the criteria outlined in the Funding Opportunity Announcement, will qualify for a higher level of funding.

    ·      Maximum funding of $500,000 for direct costs plus indirect costs

    ·      Maximum funding of $600,000 for direct costs plus indirect costs if applying for the Therapeutic Relevant Biomarker Option

    ·      Maximum period of performance is years

     

    New for FY20! Clinical Development Award - Pre-Application March 27, 2020

    Independent investigators at all academic levels (or equivalent) 

    ·      Pre-application is required; full application submission is by invitation only.

    ·      Supports leveraging of human-based ALS resources through correlative clinical research.

    ·      Early Career Investigators and/or Early Career Physician Scientists are encouraged to apply.

    ·      Types of efforts that will be supported include:

    o  Using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis

    o  Correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes

    o  Adding a secondary aim/goal to an anticipated/ongoing clinical trial, not otherwise supported by the trial

    o  Studies to evaluate optimizing components of current ALS clinical care

    ·      Maximum funding of $300,000 for direct costs plus indirect costs

    ·      Maximum period of performance is years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.  

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 14 Jan 2020 2:59 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $15 million to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The OPORP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 OPORP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. 

    OPORP supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service members and Veterans with limb loss and/or limb impairment. The intent of this research is to generate clinically useful evidence that will enhance and optimize patient outcomes. Applications submitted to the FY20 OPORP must address at least one of the following Focus Areas:

    • Orthoses or Prostheses Form: Optimize patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
    • Orthoses or Prostheses Fit: Optimize patient outcomes related to human-device interface through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
    • Orthoses or Prostheses Function: Optimize patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

    https://cdmrp.army.mil/pubs/press/2020/20oporppreann

     

    Clinical Research Award

    Independent investigators at all academic levels (or equivalent).

    • Funding Level 1 supports pilot research that has the potential to make significant advancement toward clinical translation. Preliminary data are allowed but not required.
    • Funding Level 2 supports research that has the potential to make significant impact toward clinical translation. Preliminary data and/or published data from the literature that are relevant to the orthotic and/or prosthetic device outcomes and support the rationale for the proposed research are required.
    • ·         Preclinical studies using animals are not allowed.

    Funding Level 1

    • Maximum funding of $350,000 for total costs (direct plus indirect costs).
    • Maximum period of performance is 2 years.

    Funding Level 2

    • Maximum funding of $2 million for total costs (direct plus indirect costs).
    • ·         Maximum period of performance is 4 years.

    Clinical Trial Award

    Independent investigators at all academic levels (or equivalent).

    • Supports clinical trials with the potential to have a significant impact on improving the health and well-being of Service members, Veterans, and other individuals living with limb loss and/or limb impairment.
    • Funding Level 1 supports pilot clinical trials which are exploratory and involve limited human exposure with the potential to make significant advancement toward clinical translation. Preliminary data are allowed but not required.
    • Funding Level 2 supports clinical trials with the potential to make significant advancement toward clinical translation. Preliminary data relevant to the proposed clinical trial are required.
    • Preclinical research is not allowed.

    Funding Level 1

    • Maximum funding of $350,000 for total costs (direct plus indirect costs).
    • Maximum period of performance is years.

    Funding Level 2

    • Maximum funding of $4 million for total costs (direct plus indirect costs).
    • ·         Maximum period of performance is years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 27 Dec 2019 10:49 AM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $3 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on BMF diseases. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The BMFRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 BMFRP Program Announcement and General Application Instructions for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcement is released.

    https://cdmrp.army.mil/pubs/press/2020/20bmfrppreann

    Idea Development Award

    Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from first faculty appointment (or equivalent) or

    Early Career Investigators:
    Independent investigators at the level of Assistant Professor (or equivalent) and less than 10 years from first faculty appointment (or equivalent).

    • Preproposal is required; full application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF.
    • Strong BMF research team.
    • Research project should include well-formulated, testable hypothesis based on strong scientific rationale and a well- developed and articulated research approach.
    • Translational potential should be considered and described.
    • May include relevant preliminary data.
    • Clinical trials will not be supported.
    • Maximum funding of $325,000 in direct costs (plus indirect costs).
    • Period of performance not to exceed 2 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 26 Dec 2019 3:30 PM | Hawk Tran (Administrator)

    The Fiscal Year 2020 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):

    • Amyotrophic Lateral Sclerosis Research Program - $20.0 million
    • Autism Research Program - $15.0 million
    • Bone Marrow Failure Research Program - $3.0 million
    • Breast Cancer Research Program - $150.0 million
    • Chronic Pain Management Research Program - $15.0 million
    • Combat Readiness Medical Research Program - $10.0 million
    • Duchenne Muscular Dystrophy Research Program - $10.0 million
    • Epilepsy Research Program - $12.0 million
    • Gulf War Illness Research Program - $22.0 million
    • Hearing Restoration Research Program – $10.0 million
    • Kidney Cancer Research Program - $40.0 million
    • Joint Warfighter Medical Research Program - $40.0 million
    • Lung Cancer Research Program – $14.0 million
    • Lupus Research Program - $10.0 million
    • Melanoma Research Program - $20.0 million
    • Military Burn Research Program – $10.0 million
    • Multiple Sclerosis Research Program - $16.0 million
    • Neurofibromatosis Research Program - $15.0 million
    • Orthotics and Prosthetics Outcomes Research Program- $15.0 million
    • Ovarian Cancer Research Program - $35.0 million
    • Pancreatic Cancer Research Program - $6.0 million  (new for FY 20)
    • Parkinson's Research Program – $16.0 million
    • Peer Reviewed Alzheimer's Research Program – $15.0 million
    • Peer Reviewed Cancer Research Program (14 Topics) - $110 million
    • Peer Reviewed Medical Research Program (44 Topics) - $360 million
    • Peer Reviewed Orthopaedic Research Program - $30 million
    • Prostate Cancer Research Program - $110 million
    • Rare Cancers Research Program - $7.5 million  (new for FY 20)
    • Reconstructive Transplant Research Program - $12.0 million
    • Scleroderma Research Program - $5.0 million (new for FY 20)
    • Spinal Cord Injury Research Program - $40.0 million
    • Tick-Borne Disease Research Program - $7.0 million
    • Tuberous Sclerosis Complex Research Program - $6.0 million
    • Vision Research Program - $20.0 million

    https://cdmrp.army.mil/pubs/press/2020/funding_press_release20

    Pre-announcements and comprehensive Program Announcements will be forthcoming. The pre-announcements will provide a general overview of the anticipated funding mechanisms. The Program Announcements will include detailed descriptions of funding mechanisms, evaluation criteria, submission requirements, and deadlines. Each Program Announcement may be downloaded from the Grants.gov website http://www.grants.gov, or the CDMRP website https://cdmrp.army.mil upon its release.

    For email notification when pre-announcements and Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.

    For more information about the CDMRP, our research programs, previous awardees, as well as research highlights and videos, please visit the website at https://cdmrp.army.mil.

    Point of Contact:

    CDMRP Public Affairs
    301-619-7783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 26 Dec 2019 3:30 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $10 million to the Department of Defense Military Burn Research Program (MBRP) to support a research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities. Outcomes of successful research are anticipated to benefit Service members, Veterans, and the general public.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The MBRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 MBRP Program Announcement and General Application Instructions for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcement is released. 

    The MBRP encourages applications that propose research that advances the development or refinement of interventions, technologies, or knowledge projects that will enable non-medical personnel or medical first responders to provide appropriate burn care closer to the point of injury to enhance the potential for better long-term outcomes. Applications submitted to the FY20 MBRP must address at least one of the following Focus Areas:   

    • Burn care solutions for use by non-medical first responders in a Prolonged Field Care (PFC) scenario.
    • Burn care solutions for use by the medical first responder in the pre-hospital setting (not necessarily in a PFC scenario).

    https://cdmrp.army.mil/pubs/press/2020/20mbrppreann

     

    Clinical Translational Research Award

    Independent investigators at all academic levels (or equivalent) may be named as PI in the application.

    • Supports clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, pre-clinical, or clinical research findings to the care of the burn-injured patient.
    • The proposed study must include clinical research, and may include initial proof of concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
    • Large randomized clinical trials are discouraged.
    • Preliminary data is required.
    • Animal research is not allowed.
    • ·         Pre-application is required; application submission is by invitation only.
    • Maximum funding of $1.5 million (M) for total costs (direct costs plus indirect costs)
    • ·         Maximum period of performance is 4 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 26 Dec 2019 3:28 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation provides $15 million (M) to the Department of Defense Autism Research Program (ARP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    Subject to the FY20 Congressional appropriation for ARP funding, FY20 ARP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcements are released. 

    https://cdmrp.army.mil/pubs/press/2020/20arppreann

    Clinical Trial Award

    Investigators at or above the level of Assistant Professor (or equivalent), or

    Nested Early-Career Investigator Option: Investigators at or above the level of Assistant Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:

    • Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
    • Is no more than 7 years from the receipt of a terminal degree
    • ·         Has the freedom to commit at least 50% time to the project
    • Supports research with the potential to have a major impact on the treatment and/or management of ASD.
    • Preliminary data relevant to the proposed clinical trial are required.
    • Pre-application is required; application submission is by invitation only.
    • ·         Nested Early-Career Investigator Option: Supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research.
    • Maximum funding of $2,000,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.
    • ·         Nested Early-Career Investigator Option:
    • Maximum funding of $2,300,000 for direct costs (plus indirect costs).
    • ·         Maximum period of performance is 4 years.

    Clinical Translational Research Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    • Supports early-phase, proof-of-principle clinical trials with the potential to have a major impact on the treatment and/or management of ASD.
    • Preliminary data relevant to the proposed project are required.
    • ·         Pre-application is required; application submission is by invitation only.
    • Maximum funding of $600,000 for direct costs (plus indirect costs).
    • ·         Maximum period of performance is 3 years.

     

    Idea Development Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    Multiple PI Option: 
    Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator and receive a separate award. 

    • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes. Preliminary data relevant to the proposed project are required.
    • Pre-application is required; application submission is by invitation only.
    • ·         Clinical trials or applications including a clinical trial aim are not allowed.
    • Maximum funding of $550,000 for direct costs (plus indirect costs).
    • ·         Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
  • 20 Dec 2019 9:19 AM | Hawk Tran (Administrator)

    After a two-year advocacy and grassroots campaign by ASAE and the UBIT Coalition (of which NAVREF was a part), Congress repealed a section of the 2017 tax law that required associations and other tax-exempt organizations to pay UBIT on employee benefits such as parking and transportation.

    As part of a massive, bipartisan year-end spending and tax package agreed to this week, Congress repealed a section of the 2017 tax law that required associations and other tax-exempt organizations to pay a 21 percent unrelated business income tax (UBIT) on employee benefits, such as parking and transportation. Ultimately, Congress recognized that nonprofit employee benefits like parking and transit assistance are not a trade or business conducted for the production of income and therefore should not be regarded as taxable under the UBIT statute.


  • 18 Dec 2019 10:45 AM | Hawk Tran (Administrator)

    Los Angeles, CA, November 12, 2019 - Representatives from Brentwood Biomedical Research Institute (BBRI) and Sepulveda Research Corporation (SRC) announced this week that the two nonprofit corporations of the VA Greater Los Angeles Healthcare System (VAGLAHS) merged on October 31, 2019 resulting in the Greater Los Angeles Research and Education Foundation (GLAVREF).

    BBRI and SRC are currently leading forces for VAGLAHS in providing the medical facility with flexible funding mechanisms for the conduct and functions related to approved research, education, and training at the West Los Angeles and North Hills campuses of the VA. According to GLAVREF Board Chairman Dr. David Beenhouwer, “The merger will unite BBRI and SRC into a single non-profit corporation, GLAVREF, serving the research and educational needs of

    VA Greater Los Angeles. Moving forward, this will streamline processes, increase efficiency and strengthen our ability both to provide the best services for the GLA research community and to help compete successfully for diverse funding opportunities.”

    Established in 1988, BBRI has managed funds totaling $217,137,381 to advance the mission of research and education for the health of Veterans at VAGLAHS. “The merger of BBRI and SRC joining together as GLAVREF is an exciting time in Veterans research. We are striving to become one organization that provides efficient and effective services to the research community and all stakeholders of the VAGLAHS,” noted Thoyd Ellis, Acting Executive Director/CFO at BBRI.

    Established in 1989, SRC has managed funds totaling $66,549,877 to advance the mission of research and education for the health of Veterans at North Hills VA; the system merged with VAGLAHS in 1998. Of the merger, SRC Executive Director Bonita L. Krall states “A merger has been on my radar for many years and it is exciting that GLAVREF is finally happening. It is in the best interest of our research and education community to have a single entity support their endeavors to improve the lives and well-being of our Veteran population. We look forward to continuing our proficient support to all investigators and clinicians here at GLA.”

    The new organization led by Executive Director Jane Cheung will focus on increased services, efficiency, and revenue growth. GLAVREF will officially conduct business at both the West LA and North Hills campuses starting October 31, 2019.


    CONTACT INFORMATION:

    Greater Los Angeles Veterans Research and Education Foundation

    Jane Cheung, Executive Director: (818) 895-5881


  • 17 Dec 2019 11:39 AM | Hawk Tran (Administrator)

    The Fiscal Year 2020 (FY20) Defense Appropriations Bill has not been signed into law.  Although FY20 funds have not been appropriated for the Department of Defense Neurofibromatosis Research Program (NFRP), the NFRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.

    The FY20 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact NF research.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    Subject to the FY20 Congressional appropriation for NFRP funding, FY20 NFRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcements are released.

    Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY20 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY20 NFRP.  If the proposed research project does not address one of the FY20 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided. Applications submitted to the FY20 NFRP must address one or more of the following Areas of Emphasis:

    • Biomarker discovery, utility, development, and validation
    • Non-tumor manifestations not limited to:

    o  Pain

    o  Cognitive Manifestations

    o  Sleep

    • Heterogeneity of NF-related tumors
    • Novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
    • Preclinical efficacy studies
    • Target identification, drug discovery
    • Nutritional, environmental, and other modifiers of NF
    • Health services research

    ·        Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.

    ·        Funding must support a clinical trial and may not be used for preclinical studies.

    ·        Scientific rationale and preliminary data required for Phase I, II clinical trial applications.

    ·      Maximum funding of $800,000 for direct costs (plus indirect costs)

    ·      Maximum funding of $1M for direct costs (plus indirect costs) for applications including a Collaborator

    ·      Maximum period of performance is years

    Exploration – Hypothesis Development Award

    All academic levels (or equivalent)

    ·        Funds the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in NF research.

    ·        Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

    ·        Preliminary and/or published data is encouraged but not required.

    ·        Clinical trials not allowed.

    ·      Maximum funding of $100,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 2 years

    Investigator-Initiated Research Award

    Investigators at or above the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period throughout the entirety of the award

    ·      Funds highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.

    ·      Optional Features: Applications meeting criteria identified in the announcement may apply for a higher level of funding for the following options: Qualified Collaborator and/or NF Open Science Initiative (NF-OSI).

    ·      Preliminary and/or published data is required.

    ·      Clinical trials not allowed.

    ·     Maximum funding of $525,000 for direct costs (plus indirect costs)

    ·     Maximum funding of $575,000 for direct costs (plus indirect costs) for applications including either an Optional Qualified Collaborator or NF-OSI option

    ·     Maximum funding of $625,000 for direct costs (plus indirect costs) for applications including both, an Optional Qualified

    New Investigator Award

    Investigators at or below the level of Assistant Professor (or equivalent) or an established investigator at or above the level of Assistant Professor seeking to transition into a career in NF research

    ·      Supports the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research.

    ·      Experience in NF research is allowed, but not required.

    ·      Preliminary and/or published data is required.

    ·      Clinical trials not allowed

    ·     Maximum funding of $450,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance is 3 years

    Early Investigator Research Award

    Postdoctoral Ph.D. or M.D. PIs:

    ·   Must have successfully defended a doctoral thesis or possess an M.D. degree, and

    ·   Have at least 3 years and up to 6 years of consecutive postdoctoral fellowship

    ·   Supports research opportunities focused on NF for individuals in the early stages of their careers.

    ·   PIs must have a designated mentor who is an experienced NF researcher.

    ·     Maximum funding of $200,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance is 2 years

    Synergistic Idea Award (NEW for FY20)

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports new or existing partnerships between two or three investigators to address a central innovative question or problem in NF that may be high risk, provided there is a potential for significant impact.

    ·      PIs are expected to demonstrate within the application the synergistic components (i.e., leveraging disciplines, expertise or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single PI.

    ·      Preliminary and/or published data is required.

    ·      Synergy, Research Strategy, Personnel, and Impact are the most important review criteria.

    ·      Clinical trials are not allowed.

    ·     Maximum funding of $2M for direct costs (plus indirect costs)

    ·     Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are releasedFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 17 Dec 2019 11:33 AM | Hawk Tran (Administrator)

    The Fiscal Year 2020 (FY20) Defense Appropriations Bill has not been signed into law.  Although FY20 funds have not been appropriated for the Department of Defense Tuberous Sclerosis Research Program (TSCRP), the TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities.  This pre-announcement should not be construed as an obligation by the Government.

    The FY20 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    Subject to the FY20 Congressional appropriation for TSCRP funding, FY20 TSCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcements are released

    Applications submitted to the FY20 TSCRP are encouraged to address one or more of the following Focus Areas:

    • Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
    • Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
    • Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact, including pharmacological and behavioral interventions
    • Advancing clinical trial readiness and optimizing clinical care through development of biomarkers and clinical outcome measures, patient selection and sample size determination, pharmacokinetic/pharmacodynamics (PK/PD) studies, and enhanced trial design

    https://cdmrp.army.mil/pubs/press/2020/20tscrppreann

    Exploration – Hypothesis Development Award

    Investigators at or above postdoctoral fellow (or equivalent)

    ·      Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field.

    ·      Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

    ·      Preliminary data are not required.

    ·      Research projects must be innovative, feasible, and supported by a strong rationale.

    ·      Innovation is the most important review criterion.

    ·      Clinical trials are not allowed.

    ·    Maximum funding of $150,000 for direct costs (plus indirect costs)

    ·    Maximum period of performance is 2 years

    Idea Development Award

    Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent);

    or New Investigators:

    Independent investigator at or below the level of Assistant Professor (or equivalent); or

    Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC, thereby bringing his/her expertise to the field.

    • Must not have received more than $300,000 in total direct costs for previous or concurrent TSC research as a Principal Investigator of one or more Federally funded, non-mentored peer-reviewed grants. (National Institutes of Health K Awardees are eligible to apply.)
    • Must not have received a New Investigator Award previously from any program within the CDMRP.

    ·      Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation.

    ·      Preliminary data are expected.

    ·      Impact and Innovation are important review criteria.

    ·      Clinical trials are not allowed.

    ·      New Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition or established investigators from other research fields into career in TSC research.

    ·      Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately.

    • Maximum funding of $450,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Clinical Translational Research Award

    Independent Investigators at or above the level of Assistant Professor (or equivalent)

    ·      Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.

    ·      Studies advancing clinical trial readiness through development of biomarkers, clinical endpoint, and validation of PK/PD are of particular interest.

    ·      Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research. Pilot clinical trials, including behavioral interventions, are encouraged.

    ·      Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies.

    ·      Preclinical studies may be appropriate but must include a clinical component.

    ·      Projects that are exploratory and/or strictly animal research will not be considered for funding.

    ·      Clinical Translational Potential is the most important review criterion.

    ·      Preliminary data are required.

    ·    Maximum funding of $600,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software